These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 17075808

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Nephromegaly relates to hepatocyte growth factor dysregulation in biliary atresia.
    Tsau YK, Jou ST, Ni YH.
    Pediatr Nephrol; 2002 Jul; 17(7):554-9. PubMed ID: 12172775
    [Abstract] [Full Text] [Related]

  • 24. Renal pathology and long-term outcome in childhood SLE.
    Sumboonnanonda A, Vongjirad A, Suntornpoch V, Laohapand T, Parichatikanond P.
    J Med Assoc Thai; 1998 Nov; 81(11):830-4. PubMed ID: 9803081
    [Abstract] [Full Text] [Related]

  • 25. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.
    Mok CC, Ho CT, Chan KW, Lau CS, Wong RW.
    Arthritis Rheum; 2002 Apr; 46(4):1003-13. PubMed ID: 11953978
    [Abstract] [Full Text] [Related]

  • 26. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis.
    Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT.
    Nephrol Dial Transplant; 2005 Jan; 20(1):96-104. PubMed ID: 15546891
    [Abstract] [Full Text] [Related]

  • 27. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis.
    Demircin G, Oner A, Erdoğan O, Delibaş A, Baysun S, Bülbül M, Bek K, Oksal A.
    Ren Fail; 2008 Jan; 30(6):603-9. PubMed ID: 18661410
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature.
    Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M.
    Q J Med; 1989 Sep; 72(269):779-833. PubMed ID: 2694209
    [Abstract] [Full Text] [Related]

  • 32. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
    Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG.
    Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
    [Abstract] [Full Text] [Related]

  • 33. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
    Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED.
    Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
    [Abstract] [Full Text] [Related]

  • 34. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
    Grootscholten C, Snoek FJ, Bijl M, van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party of SLE.
    J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
    [Abstract] [Full Text] [Related]

  • 35. Renal alpha-smooth muscle actin: a new prognostic factor for lupus nephritis.
    Makni K, Jarraya F, Khabir A, Hentati B, Hmida MB, Makni H, Boudawara T, Jlidi R, Hachicha J, Ayadi H.
    Nephrology (Carlton); 2009 Aug; 14(5):499-505. PubMed ID: 19674318
    [Abstract] [Full Text] [Related]

  • 36. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide.
    Cunnane G, Chan OT, Cassafer G, Brindis S, Kaufman E, Yen TS, Daikh DI.
    Arthritis Rheum; 2004 May; 50(5):1539-48. PubMed ID: 15146424
    [Abstract] [Full Text] [Related]

  • 37. The benefit of early treatment with immunosuppressive agents in lupus nephritis.
    Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP.
    J Rheumatol; 1994 Nov; 21(11):2046-51. PubMed ID: 7869308
    [Abstract] [Full Text] [Related]

  • 38. Prognostic factors in diffuse proliferative lupus nephritis.
    Abraham MA, Korula A, Jayakrishnan K, John GT, Thomas PP, Jacob CK.
    J Assoc Physicians India; 1999 Sep; 47(9):862-5. PubMed ID: 10778652
    [Abstract] [Full Text] [Related]

  • 39. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study.
    Tanaka H, Oki E, Tsugawa K, Nonaka K, Suzuki K, Ito E.
    Lupus; 2007 Sep; 16(11):896-900. PubMed ID: 17971363
    [Abstract] [Full Text] [Related]

  • 40. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients.
    Enghard P, Humrich JY, Rudolph B, Rosenberger S, Biesen R, Kuhn A, Manz R, Hiepe F, Radbruch A, Burmester GR, Riemekasten G.
    Arthritis Rheum; 2009 Jan; 60(1):199-206. PubMed ID: 19116922
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.